Publications

Bauer, D., D.F. Staskal, J.J. Diliberto, and L.S. Birnbaum. 2005. Disposition of BDE 99 and BDE 153 in female mice. Society of Toxicology. March 6-10, 2005. New Orleans, LA.

Perry, C.S., Garcia, S., Collie, S., MacDonell, M., Femi Adeshina, and Cynthia Sonich-Mullin: Application of provisional advisory levels for EPA National Homeland Security Research Center’s secure, internet-based rapid risk tool. Society for Risk Analysis’ Annual Meeting. December 4-7, 2005. Orlando, FL.

Urban JD, Mailman RB. 2005. Characterization of the N27 dopaminergic cell line as a model for elucidating the actions of functionally selective dopaminergic ligands. 35th Annual Neuroscience Meeting, Washington, DC, November 2005.

Grasty RC, N Roberts, G Klinefelter, JA Bjork, KB Wallace, CS Lau, and JM Rogers (2005). Effects of prenatal perfluorooctanesulfonate (PFOS) exposure on lung maturation in the perinatal rat. Birth Defects Res A Clin Mol Teratol 73: 314.

Perry, C.S. and Morton, E. Lessons learned from creating integrated Excel models to calculate human health screening values. Society for Risk Analysis’ Annual Meeting. December 5-8, 2004. Palm Springs, CA.

Staskal, D.F., J.J. Diliberto, M.J. DeVito, and L.S. Birnbaum. 2004. Tissue distribution and elimination of BDE 47 in mice following a single oral dose.  Dioxin 2004. September 6-10, 2004. Berlin, Germany.

Staskal, D.F., J.J. Diliberto, M.J. DeVito, and L.S. Birnbaum. 2004. Disposition of 2,2’,4,4’-Tetrabromodiphenylether (BDE 47) in Female Mice. 43rd Annual Meeting of Society for Toxicology. March 21-25, 2004. Baltimore, MD.

Urban JD, Gay EA, Mailman RB 2004. Functional selectivity as a mechanism of action of newer atypical antipsychotic drugs. 34th Annual Neuroscience Meeting, San Diego, CA, October 2004.

Grasty RC, Roberts N, Grey BE, Lau C, Rogers JM. (2004). Effects of prenatal exposure to perfluorooctane sulfonate on the developing lung in the rat. 43rd Annual Meeting of Society for Toxicology. March 21-25, 2004. Baltimore, MD.

Urban JD, Gay EA, Mailman RB. Decreased neurological side-effects with aripiprazole: A result of functional selectivity of the D2 receptor? Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.